This document is a presentation from Botanix Pharmaceuticals Limited, discussing their plans for the commercial launch of Sofdra, a newly FDA-approved treatment for primary axillary hyperhidrosis (excessive underarm sweating). Here are the key points:
1. Company Overview:
- US-based team with experience in dermatology drug development and launches
- Well-capitalized with ~A$79 million to fund Sofdra's launch
- Plans first sales in Q4 2024
2. Market Opportunity:
- ~10 million axillary hyperhidrosis patients in the US
- ~3.7 million priority target patients seeking prescription treatment
3. Commercial Strategy:
- Three-pillar approach: convert existing patients, activate new patients, and ensure product access and refills
- Launching a Patient Experience Program (PEP) in Q4 2024
- Full commercial launch planned for Q1 2025
- Targeting both dermatologists and patients directly through telemedicine
4. Patient Insights:
- Survey results show high interest in new, effective treatments
- Patients willing to tolerate some side effects for effective treatment
5. Marketing and Patient Acquisition:
- Partnering with Klick Health for digital marketing
- Using data-driven approach to identify and target potential patients
- Leveraging telemedicine to increase access and speed to prescription
6. Telemedicine Partnership:
- Working with UpScript for telemedicine consultations and prescriptions
- Aiming for quick turnaround times from consultation to prescription
7. Reimbursement and Market Access:
- Engaged with major payers and pharmacy benefit managers
- Expecting good coverage with most commercial plans
- Offering $0 co-pay for qualified commercial patients
8. Launch Timeline:
- Phased approach from September 2024 through 2025
- Includes hiring sales team, attending conferences, and scaling up marketing efforts.
(20min delay)